trial · primary record
CLN-049
AML (Acute Myeloid Leukemia)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 90 |
| Primary completion | 2030-08-31 |
| Primary endpoint | Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax |
| Registry ID | NCT07722767 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:57.571Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07722767
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cln-049 · compound